ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Inventory-to-Revenue : 0.00 (As of Dec. 2023)

---

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory-to-Revenue Chart

---

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue falls into.

---

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Inventory for the six months ended in Dec. 2023 is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Total Inventories Revenue Days Inventory Cost of Goods Sold Inventory Turnover

---

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you